Unknown

Dataset Information

0

Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells.


ABSTRACT: Purpose: Targeted treatment of breast cancer through combination of chemotherapeutic agents and siRNA had been drawing much attention in recent researches. This study was carried out to evaluate mucin1 aptamer-conjugated chitosan nanoparticles containing docetaxel and cMET siRNA on SKBR3 cells. Methods: Nano-drugs were characterized by transmission electron microscope, Zetasizer and loading efficiency calculation. siRNA entrapment onto nanoparticles, stability of siRNA-loaded nanoparticles and conjugation of mucin1 aptamer to nanoparticles were evaluated via separate electrophoresis. Cellular uptake of the targeted nanoparticles was evaluated through GFP-plasmid expression in mucin1+ SKBR3 vs. mucin1- CHO cells. Protein expression, cell viability and gene expression were assessed by Western Blotting, MTT assay, and Quantitative Real Time-PCR, respectively. Results: Characterization of nano-drugs represented the ideal size (110.5± 3.9 nm), zeta potential (11.6± 0.8 mV), and loading efficiency of 90.7% and 88.3% for siRNA and docetaxel, respectively. Different gel electrophoresis affirmed the conjugation of aptamers to nanoparticles and entrapment of siRNA onto nanoparticles. Increased cellular uptake of aptamer-conjugated nanoparticles was confirmed by GFP expression. cMET gene silencing was confirmed by Western Blotting. The significant (p ?0.0001) impact of combination targeted therapy vs. control on cell viability was shown. Results of Quantitative Real Time-PCR represented a remarkably decreased (p ?0.0001) expression of the studied genes involving in tumorigenicity, metastasis, invasion, and angiogenesis (STAT3, IL8, MMP2, MMP9, and VEGF) by targeted combination treatment vs. control. Conclusion: The mucin1 aptamer-conjugated chitosan nanoparticles, containing docetaxel and cMET siRNA, is suggested for treatment of mucin1+ metastatic breast cancer cells. However, further studies should be conducted on animal models.

SUBMITTER: Majidi Zolbanin N 

PROVIDER: S-EPMC6156474 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells.

Majidi Zolbanin Naime N   Jafari Reza R   Majidi Jafar J   Atyabi Fatemeh F   Yousefi Mehdi M   Jadidi-Niaragh Farhad F   Aghebati-Maleki Leili L   Shanehbandi Dariush D   Soltani Zangbar Mohammad-Sadegh MS   Nayebi Alireza Mohajjel AM  

Advanced pharmaceutical bulletin 20180829 3


<b><i>Purpose:</i></b> Targeted treatment of breast cancer through combination of chemotherapeutic agents and siRNA had been drawing much attention in recent researches. This study was carried out to evaluate mucin1 aptamer-conjugated chitosan nanoparticles containing docetaxel and cMET siRNA on SKBR3 cells. <b><i>Methods:</i></b> Nano-drugs were characterized by transmission electron microscope, Zetasizer and loading efficiency calculation. siRNA entrapment onto nanoparticles, stability of siRN  ...[more]

Similar Datasets

| S-EPMC6305820 | biostudies-other
| S-EPMC6273023 | biostudies-literature
| S-EPMC4150469 | biostudies-literature
| S-EPMC2890121 | biostudies-literature
| S-EPMC5173113 | biostudies-literature
| S-EPMC5224624 | biostudies-literature
| S-EPMC6409946 | biostudies-literature
| S-EPMC5666711 | biostudies-literature
| S-EPMC6136846 | biostudies-other
| S-EPMC2765502 | biostudies-literature